A review of the treatment options for Huntington’s disease

Bibliography

• HARPER PS: The epidemiology of Huntington's disease. Hum. Genet. (1992) 89:365–376.
   PubMedGoogle Scholar
• SHIWACH R: Psychopathology in Huntington's disease patients. Acta Psychiatr. Scand. (1994) 90:241–246.
   Google Scholar
• HUNTINGTON'S DISEASE COLLABORATIVE RESEARCH GROUP: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell (1993) 72:971–983.
   PubMedGoogle Scholar
• •A key paper on the genetics of HD.
   Google Scholar
• KREMER B, GOLDBERGP, ANDREW SE et al.: A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl. J. Med. (1994) 330:1401–1406.
   Google Scholar
• KREMER B: Clinical neurology of Huntington's disease. In: Huntington's disease. Bates G et al. (Eds), Oxford University Press, Oxford, UK (2002):28–61.
   Google Scholar
• ••An excellent review on the clinicalneurology of HD.
   Google Scholar
• ANDREW SE, GOLDBERG YP, KREMER B et al: The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. (1993) 4:398–403.
   PubMed Web of Science ®Google Scholar
• HEDREEN JC, FOLSTEIN SE: Early loss of neostriatal striosome neurons in Huntington's disease. Neuropathol Exp. Neurol (1995) 54:105–120.
   PubMedGoogle Scholar
• TURJANSKI N, WEEKS R, DOLAN R, HARDING AE, BROOKS DJ: Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain (1995) 118:689–696.
   PubMed Web of Science ®Google Scholar
• GINOVART N, LUNDIN A, FARDE L et al.: PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain (1997) 120:503–514.
   PubMed Web of Science ®Google Scholar
• HUNTINGTON G: On chorea. Med. Surg. Rep. (1872) 26:317–321.
   Google Scholar
• •The original paper of Gerorge Huntington. It is worth reading his excellent description.
   Google Scholar
• WESTPHAL C: Tiber eine dem Bilde der cerebrospinalen grauen Degeneration ähnlichen Erkrankung des centralen Nervensystems ohne anatomischen Befund, nebst einigen Bemerkungen über paradoxe Contraktionen. Arch. Psychiati: Nervenkr: (1883) 14:187–234.
   Google Scholar
• CRAUFORD D, SNOWDEN J: Neuropsychological and neuropsychiatric aspects of Huntington's disease. In: Huntington's disease. Bates G et al. (Eds), Oxford University Press, Oxford, UK (2002):62–94.
   Google Scholar
• ••The best and latest review on neuropsychological and neuropsychiatric aspects of HD we found.
   Google Scholar
• WEINGARTNER H, CAINE ED, EBERT MH: Imagery, encoding, and retrieval of information from memory: some specific encoding-retrieval changes in Huntington's disease. Abnorm. Psycho]. (1979) 88:52–58.
   PubMedGoogle Scholar
• BUTTERS N: The clinical aspects of memory disorders: contributions from experimental studies of amnesia and dementia. Clin. Neuropsychol (1984) 6:17–36.
   Google Scholar
• MOSKOWITZ CB, MARDER K: Palliative care for people with late-stage Huntington's disease. Neurol Clin. (2001) 19:849–865.
   PubMed Web of Science ®Google Scholar
• FISHER JM, KENNEDY JL, CAINE ED,SHOULSON I: Dementia in Huntington's disease: a cross-sectional analysis of intellectual decline. Adv. Neurol (1983) 38:229–238.
   PubMedGoogle Scholar
• KNOPMAN D, NISSEN MJ: Procedural learning is impaired in Huntington's disease: evidence from the serial reaction time task. Neuropsychologia (1991) 29:245–254.
   PubMed Web of Science ®Google Scholar
• RANEN NG, PEYSER CE, FOLSTEIN SE: A physicians guide to the management of Huntington's disease. Huntington's Disease Society of America, New York, USA (1993).
   Google Scholar
• FOLSTEIN SE: Huntington's disease: a disorder of families. Johns Hopkins University Press, Baltimore, MD, USA (1989): 251.
   Google Scholar
• VITALE C, PELLECCHIA MT, GROSSI D et al.: Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci. (2001) 22:105–106.
   Google Scholar
• SNOWDEN JS, CRAUFURD D, GRIFFITHS HL, NEARY D: Awareness of involuntary movements in Huntington's disease. Arch. Neurol (1998) 55:801–805.
   PubMed Web of Science ®Google Scholar
• TYLER A, SCOURFIELD J, MORRIS M: Management and therapy of Huntington's disease. In: Huntington's disease. Harper P (Ed.), Saunders Company, London, UK (1996) :161–200.
   Google Scholar
• BONELLI RM, THAU K: Noncompliance: em n Oberblick. Dtsch. Med. Wochenschr: (2001) 126:699–703.
   PubMedGoogle Scholar
• DURSUN SM, BURKE JG, ANDREWS H, MLYNIK-SZMID A, REVELEY MA: The effects of antipsychotic medication on saccadic eye movement abnormalities in Huntington's disease. Frog. Neuropsychopharmacol Biol. Psychiatry (2000) 24:889–896.
   Google Scholar
• YOUNG AB, SHOULSON I, PENNEY JB et al.: Huntington's disease in Venezuela: neurologic features and functional decline. Neurology (1986) 36:244–249.
   Google Scholar
• SCHOTT K, RIED S, STEVENS I, DICHGANS J: Neuroleptically induced dystonia in Huntington's disease: a case report. Eur: Neurol (1989) 29:39–40.
   PubMedGoogle Scholar
• LOUIS ED, LEE P, QUINN L, MARDER K: Dystonia in Huntington's disease: prevalence and clinical characteristics. Mov. Disord. (1999) 14:95–101.
   PubMed Web of Science ®Google Scholar
• GIMENEZ-ROLDAN S, MATEO D: Enfermedad de Huntington: tetrabenacina comparada con haloperidol en la reduccion de los movimientos involuntarios. Neurologia (1989) 4:282–287.
   PubMedGoogle Scholar
• BARR AN, FISCHER JH, KOLLER WC, SPUNT AL, SINGHAL A: Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology (1988) 38:84–88.
   PubMed Web of Science ®Google Scholar
• •The key paper on haloperidol in HD.
   Google Scholar
• ARENA R, IUDICE A, VIRGILI P, MORETTI P, MENCHETTI G: Huntington's disease: clinical effects of a short-term treatment with pimozide. Adv. Biochem. Psychopharmacol (1980) 24:573–575.
   PubMedGoogle Scholar
• GIROTTI F, CARELLA F, SCIGLIANO Get al.: Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. Neuro/. Neurosurg. Psychiatry (1984) 47:848–852.
   PubMed Web of Science ®Google Scholar
• TERRENCE CF: Fluphenazine decanoate in the treatment of chorea: a double-blind study. Carr: Ther. Res. Clin. Exp. (1976) 20:177–183.
   PubMed Web of Science ®Google Scholar
• KORENYI C, WHITTIER JR: Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (Prolixin). Psychiatr. Q. (1967) 41:203–210.
   Google Scholar
• WHITTIER JR, KORENYI C: Effect of oral fluphenazine on Huntington's chorea. Int. J. Neuropsychiatry (1968) 4: 1–3.
   Google Scholar
• QUINN N, MARSDEN CD: A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. Neurol Neurosurg. Psychiatry(1984) 47: 844–847.
   Google Scholar
• DEROOVER J, BARO F, BOURGUIGNON RP, SMETS P: Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Carr: Med. Res. Opin. (1984) 9:329–338.
   PubMed Web of Science ®Google Scholar
• ROOS RA, BURUMA 0J, BRUYN GW, KEMP B, VAN DER VELDE EA: Tiapride in the treatment of Huntington's chorea. Acta Nemo]. Scand. (1982) 65:45–50.
   PubMed Web of Science ®Google Scholar
• ASHER SW, AMINOFF MJ: Tetrabenazine and movement disorders. Neurology(1981) 31: 1051–1054.
   Google Scholar
• SWASH M, ROBERTS AH, ZAKKO H, HEATHFIELD KW: Treatment of involuntary movement disorders with tetrabenazine. Neural. Neurosurg. Psychiatry (1972) 35:186–188.
   PubMedGoogle Scholar
• JANKOVIC J, BEACH J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology (1997) 48:358–362.
   PubMed Web of Science ®Google Scholar
• BURKE RE, FAHN S, MAYEUX R et al:Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington's disease. Neurology (1981) 31:1022–1025.
   PubMed Web of Science ®Google Scholar
• MATEO D, MUNOZ-BLANCO JL, GIMENEZ-ROLDAN S: Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin. Neuropharmacol (1992) 15:63–68.
   PubMed Web of Science ®Google Scholar
• OSSEMANN M, SINDIC CJ, LATERRE C: Tetrabenazine as a cause of neuroleptic malignant syndrome. Mo v. Disord. (1996) 11:95.
   PubMed Web of Science ®Google Scholar
• SQUITIERI F, CANNELLA M, PIORCELLINI A et al.: Short-term effects of olanzapine in Huntington's disease. Neuropsychiatry Neuropsychol Behav. Neurol (2001) 14:69–72.
   PubMedGoogle Scholar
• PALEACU D, ANCA M, GILADI N: Olanzapine in Huntington's disease. Acta Nemo]. Scand. (2002) 105:441–444.
   PubMed Web of Science ®Google Scholar
• BONELLI PM, MAHNERT FA, NIEDERWIESER G: Olanzapine for Huntington's disease: an open label study. Neuropharmacol (2002) 25:263–265.
   Google Scholar
• DALLOCCHIO C, BUFFA C, TINELLI C, MAZZARELLO P: Effectiveness of risperidone in Huntington chorea patients. I Gin. Psychopharmacol (1999) 19:101–103.
   Google Scholar
• BONELLI PM, NIEDERWIESER G: Quetiapine in Huntington's disease: a first case report. Neurol (2002) 249:1114–1115.
   Google Scholar
• VAN VUGT JP, SIESLING S, VERGEER M, VAN DER VELDE EA, ROOS RA: Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J. Neurol Neurosurg. Psychiatry (1997) 63:35–39.
   Google Scholar
• VERHAGEN METMAN L, MORRIS MJ, FARMER C et al: Huntington's disease: a randomized, controlled trial using the NMDA- antagonist amantadine. Neurology (2002) 59:694–699.
   PubMed Web of Science ®Google Scholar
• •A well-conducted study on amantadine.
   Google Scholar
• O'SUILLEABHAIN P, DEWEY RB Jr: A randomized trial of amantadine in Huntington's disease. Arch. Neurol (2003) 60:996–998.
   Google Scholar
• SEPPI K, MUELLER J, BODNER T et al:Riluzole in Huntington's disease (HD): an open label study with one year follow up. Neurol (2001) 248:866–869.
   Google Scholar
• ROSAS HD, KOROSHETZ WJ, JENKINS BG et al.: Riluzole therapy in Huntington's disease (HD). Mov. Disord. (1999) 14:326–330.
   Google Scholar
• MURMAN DL, GIORDANI B, MELLOW AM et al.: Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology (1997) 49:153–161.
   PubMed Web of Science ®Google Scholar
• KIEBURTZ K, FEIGIN A, MCDERMOTT M et al: A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Disord. (1996) 11:273–277.
   PubMed Web of Science ®Google Scholar
• GIUFFRA ME, MOURADIAN MM, CHASE TN: Glutamatergic therapy of Huntington's chorea. Neuropharmacol (1992) 15:148–151.
   Google Scholar
• PERRY TL, WRIGHT JM, HANSEN Set al.: A double-blind clinical trial of isoniazid in Huntington's disease. Neurology (1982) 32:354–358.
   PubMedGoogle Scholar
• MANYAM BV, KATZ L, HARE TA, KANIEFSKI K, TREMBLAY RD: Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease. Ann. Neurol (1981) 10:35–37.
   Google Scholar
• MANYAM BV, FERRARO TN, HARE TA: Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease. Brain Res. (1987) 408:125–130.
   PubMedGoogle Scholar
• SCIGLIANO G, GIOVANNINI P, GIROTTI F et al.: Gamma-vinyl GABA treatment of Huntington's disease. Neurology (1984) 34:94–96.
   PubMedGoogle Scholar
• FOSTER NL, CHASE TN, DENARO A, HARE TA, TAMMINGA CA: THIP treatment of Huntington's disease. Neurology (1983) 33:637–639.
   PubMedGoogle Scholar
• GOETZ CG, TANNER CM, COHEN JA et al.: L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov. Disord. (1990) 5:263–265.
   Google Scholar
• PERRY TL, WRIGHT JM, HANSEN S et al.: Failure of aminooxyacetic acid therapy in Huntington's disease. Neurology (1980) 30:772–775.
   PubMed Web of Science ®Google Scholar
• SHOULSON I, GOLDBLATT D, CHARLTON M, JOYNT RJ: Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann. Neurol (1978) 4:279–284.
   PubMed Web of Science ®Google Scholar
• SHOULSON I, ODOROFF C, OAKES D et al.: A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol (1989) 25:252–259.
   PubMed Web of Science ®Google Scholar
• SYMINGTON GR, LEONARD DP, SHANNON PJ, VAJDA FJ: Sodium valproate in Huntington's disease. Am. J. Psychiatry (1978) 135: 352–354.
   Google Scholar
• HUNTINGTON STUDY GROUP: Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. (1996) 11:136–142.
   Google Scholar
• •This paper is essential for all clinical scientists.
   Google Scholar
• ZAPPACOSTA B, MONZA D, MEONI C et al: Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch. Neurol (1996) 53:493–497.
   Google Scholar
• WEIGELL-WEBER M, SCHMID W, SPIEGEL R: Psychiatric symptoms and CAG expansion in Huntington's disease. Am. J. Med. Genet. (1996) 67:53–57.
   PubMedGoogle Scholar
• OLIVER JE: Huntington's chorea in Northamptonshire. Br. .1. Psychiatry (1970) 116:241–253.
   Google Scholar
• FOLSTEIN S, ABBOTT MH, CHASE GA, JENSEN BA, FOLSTEIN MF: The association of affective disorder with Huntington's disease in a case series and in families. Psycho]. Med. (1983) 13:537–542.
   Google Scholar
• WATT DC, SELLER A: A clinico-genetic study of psychiatric disorder in Huntington's chorea. Psychol. Med. (1993) (Suppl. 23):1–46; Erratum in: Psychol. Med. (1994) 24(2):540.
   Google Scholar
• JENSEN P, SORENSEN SA, FENGER K, BOLWIG TG: A study of psychiatric morbidity in patients with Huntington's disease, their relatives, and controls. Admissions to psychiatric hospitals in Denmark from 1969 to 1991. Br. J. Psychiatry (1993) 163:790–797.
   Google Scholar
• MARDER K, ZHAO H, MYERS RH et al.: Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology (2000) 54:452–458.
   PubMed Web of Science ®Google Scholar
• •A well-conducted study on the rate of functional decline in HD based on the UHDRS.
   Google Scholar
• MENDEZ MF: Huntington's disease: update and review of neuropsychiatric aspects. Int. J. Psychiatry Med. (1994) 24:189–208.
   PubMed Web of Science ®Google Scholar
• CAINE ED, SHOULSON I: Psychiatric syndromes in Huntington's disease. Am. J. Psychiatry (1983) 140:728–733.
   PubMed Web of Science ®Google Scholar
• BONUCCELLI U, CERAVOLO R, MAREMMANI C et al.: Clozapine in Huntington's chorea. Neurology (1994) 44:821–823.
   PubMed Web of Science ®Google Scholar
• COLOSIMO C, CASSETTA E, BENTIVOGLIO AR, ALBANESE A: Clozapine in Huntington's disease. Neurology (1995) 45:1023–1024.
   PubMedGoogle Scholar
• MADHUSOODANAN S, BRENNER R: Use of risperidone in psychosis associated with Huntington's disease. Am. I Geriatr. Psychiatry (1998) 6:347–349.
   PubMed Web of Science ®Google Scholar
• ERDEMOGLU AK, BORATAV C: Risperidone in chorea and psychosis of Huntington's disease. Eurj Neurol (2002) 9:182–183.
   Google Scholar
• EVANS HJ, PEDERSEN C, TANCER ME: ECT in the treatment of organic psychosis in Huntington's disease. Convuls. Ther. (1987) 3:145–150.
   Google Scholar
• PFLANZ S, BESSON JA, EBMEIER KP,SIMPSON S: The clinical manifestation of mental disorder in Huntington's disease: a retrospective case record study of disease progression. Acta Psychiatr. Scand. (1991) 83:53–60.
   Google Scholar
• NANCE MA, SANDERS G: Characteristics of individuals with Huntington's disease in long-term care. Mo v. Disord. (1996) 11:542–548.
   PubMed Web of Science ®Google Scholar
• JENSEN P, FENGER K, BOLWIG TG, SORENSEN SA: Crime in Huntington's disease: a study of registered offences among patients, relatives, and controls. J. Nemo]. Neurosurg. Psychiatry (1998) 65:467–471.
   PubMed Web of Science ®Google Scholar
• LEONARD DP, KIDSON MA, BROWN JG, SHANNON PJ, TARYAN S: A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust. N41. Psychiatry(1975) 9:115-118.
   Google Scholar
• STEWART JT, MOUNTS ML, CLARK RL, JR.: Aggressive behavior in Huntington's disease: treatment with propranolol. Clin. Psychiatry (1987) 48:106–108.
   PubMedGoogle Scholar
• RANEN NG, LIPSEY JR, TREISMAN G,ROSS CA: Sertraline in the treatment of severe aggressiveness in Huntington's disease. I Neuropsychiatry Clin. Neurosci. (1996) 8:338–340.
   PubMed Web of Science ®Google Scholar
• DE MARCHI N, DANIELE F, RAGONE MA: Fluoxetine in the treatment of Huntington's disease. Psychopharmacology (Berl) (2001) 153:264–266.
   PubMed Web of Science ®Google Scholar
• GROVE VE, JR., QUINTANILLA J, DEVANEY GT: Improvement of Huntington's disease with olanzapine and valproate. N Engl. J. Med. (2000) 343:973–974.
   PubMed Web of Science ®Google Scholar
• BHANDARY AN, MASAND PS: Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Psychosomatics (1997) 38:389–391.
   PubMed Web of Science ®Google Scholar
• BYRNE A, MARTIN W, HNATKO G: Beneficial effects of buspirone therapy in Huntington's disease. Am. j Psychiatry (1994) 151:1097.
   PubMed Web of Science ®Google Scholar
• FINDLING RL: Treatment of aggression injuvenile-onset Huntington's disease with buspirone. Psychosomatics (1993) 34:460–461.
   PubMed Web of Science ®Google Scholar
• BLASS DM, STEINBERG M, LEROI I, LYKETSOS CG: Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. Am. J. Psychiatry (2001) 158:1966–1972.
   PubMed Web of Science ®Google Scholar
• RICH SS, OVSIEW F: Leoptolide acetate for exhibitionism in Huntington's disease. Mov. Disord. (1994) 9:353–357.
   PubMed Web of Science ®Google Scholar
• SLAUGHTER JR, MARTENS MP, SLAUGHTER KA: Depression and Huntington's disease: prevalence, clinical manifestations, etiology, and treatment. CNS Spectrums (2001) 6:306-326.
   PubMedGoogle Scholar
• LEVY ML, CUMMINGS JL, FAIRBANKS LA et al.: Apathy is not depression. I Neuropsychiamy Clin. Neurosci. (1998) 10:314–319.
   PubMed Web of Science ®Google Scholar
• LIPE H, SCHULTZ A, BIRD TD: Risk factors for suicide in Huntington's disease: a retrospective case controlled study. Am. J. Med. Genet. (1993) 48:231–233.
   PubMed Web of Science ®Google Scholar
• DI MAIO L, SQUITIERI F, NAPOLITANO G et al.: Suicide risk in Huntington's disease. J. Med. Genet. (1993) 30:293–295.
   Google Scholar
• FARRER LA: Suicide and attempted suicidein Huntington's disease: implications for preclinical testing of persons at risk. Am. J. Med. Genet. (1986) 24:305–311.
   PubMed Web of Science ®Google Scholar
• RANEN NG, PEYSER CE, FOLSTEIN SE: ECT as a treatment for depression in Huntington's disease. I Neuropsychiatiy Neurosci. (1994) 6:154-159.
   Google Scholar
• WHITTIER JR, HAYDU GG, CRAWFORD MA: Effect of imipramine on depression and hyperkinesia in Huntington's disease. Am. I Psychiatry (1962) 118:79.
   Google Scholar
• PATEL SV, TARIOT PN, ASNIS J: L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease. Ann. Clin. Psychiatry (1996) 8:23–26.
   PubMedGoogle Scholar
• FORD MF: Treatment of depression in Huntington's disease with monoamine wddase inhibitors. Br. J. Psychiatry (1986) 149:654–656.
   PubMed Web of Science ®Google Scholar
• MOLDAWSKY RJ: Effect of amoxapine on speech in a patient with Huntington's disease. Am..! Psychiatry (1984) 141:150.
   PubMedGoogle Scholar
• BONELLI RM: Mirtazapine in suicidal Huntington's disease. Ann. Pharmacother: (2003) 37:452.
   PubMed Web of Science ®Google Scholar
• SAJATOVIC M, VERBANAC P, RAMIREZ LF, MELTZER HY: Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology (1991) 41:156.
   PubMed Web of Science ®Google Scholar
• STEWART JT: Huntington's disease and propranolol. Am. I Psychiatry (1993) 150:166–167.
   PubMed Web of Science ®Google Scholar
• CAINE ED, HUNT RD, WEINGARTNER H, EBERT MH: Huntington's dementia. Clinical and neuropsychological features. Arch. Gen. Psychiatry(1978) 35: 377–384.
   Google Scholar
• PEYSER CE, FOLSTEIN SE: Huntington's disease as a model for mood disorders. Clues from neuropathology and neurochemistry. Mol. Chem. Neuropathol. (1990) 12:99–119.
   PubMedGoogle Scholar
• PEIRIS JB, BORALESSA H, LIONEL ND: Clonazepam in the treatment of choreiform activity. Med.' Aust. (1976) 1:225–227.
   Google Scholar
• STEWART JT: Treatment of Huntington's disease with clonazepam. South Med. j (1988) 81:102.
   PubMed Web of Science ®Google Scholar
• FARRELL DF, HOFMANN WW: A quantitative evaluation of the effect of diazepam in Huntington's chorea. Arch. Phys. Med. Rehabil. (1968) 49:586–591.
   PubMedGoogle Scholar
• CUMMINGS JL, CUNNINGHAM K: Obsessive-compulsive disorder in Huntington's disease. Biol. Psychiatry (1992) 31:263–270.
   PubMed Web of Science ®Google Scholar
• MCHUGH PR, FOLSTEIN MF: Psychiatric syndrome of Huntington's chorea. In: Psychiatric aspects of neurological disease. Benson DF et al. (Eds), Grune & Stratton, New York, USA (1975):267–288.
   Google Scholar
• SCICUTELLA A: Late-life obsessive-compulsive disorder and Huntington's disease. I Neuropsychiatry Clin. Neurosci. (2000) 12:288–289.
   Google Scholar
• DE MARCHI N, MORRIS M, MENNELLA R, LA PIA S, NESTADT G: Association of obsessive-compulsive disorder and pathological gambling with Huntington's disease in an Italian pedigree: possible association with Huntington's disease mutation. Acta Psychiatr. Scand. (1998) 97:62–65.
   Google Scholar
• ANDERSON KE, LOUIS ED, STERN Y, MARDER KS: Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease. Am. I Psychiatry (2001) 158:799–801.
   PubMed Web of Science ®Google Scholar
• MAYEUX R, STERN Y, ROSEN J, BENSON F: Is 'subcortical dementia' a recognizable clinical entity? Ann. Neurol. (1983) 14:278–283.
   Google Scholar
• ZAKZANIS KK: The subcortical dementia of Huntington's disease. I. Clin. Exp. Neuropsychol. (1998) 20:565–578.
   PubMed Web of Science ®Google Scholar
• BATES G: Huntingtin aggregation and toxicity in Huntington's disease. Lancet (2003) 361:1642–1644.
   PubMed Web of Science ®Google Scholar
• GUTEKUNST CA, LEVEY AI, HEILMAN CJ et al.: Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA (1995) 92:8710–8714.
   PubMedGoogle Scholar
• SHARP AH, LOEV SJ, SCHILLING G et al.: Widespread expression of Huntington's disease gene (IT15) protein product. Neuron (1995) 14:1065–1074.
   PubMedGoogle Scholar
• VONSATTEL JP, MYERS RH, STEVENS TJ et al.: Neuropathological classification of Huntington's disease. Neuropathol. Exp. Neurol. (1985) 44:559–577.
   PubMed Web of Science ®Google Scholar
• HUNTINGTON STUDY GROUP: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology (2001) 57:397–404.
   PubMed Web of Science ®Google Scholar
• ••The most relevant study onneuroprotection in HD ever made.
   Google Scholar
• KREMER B, CLARK CM, ALMQVIST EW et al.: Influence of lamotrigine on progression of early Huntington's disease: a randomized clinical trial. Neurology(1999) 53: 1000–1011.
   Google Scholar
• RANEN NG, PEYSER CE, COYLE JT et al.: A controlled trial of idebenone in Huntington's disease. Mov. Disord. (1996) 11:549–554.
   PubMed Web of Science ®Google Scholar
• PEYSER CE, FOLSTEIN M, CHASE GA et al.: Trial of d-alpha-tocopherol in Huntington's disease. Am. I Psychiatry (1995) 152:1771–1775.
   PubMed Web of Science ®Google Scholar
• HUNTINGTON STUDY GROUP: Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology (1998) 50:1366–1373.
   PubMed Web of Science ®Google Scholar
• PURI BK, BYDDER GM, COUNSELL SJ et al.: MRI and neuropsychological improvement in Huntington's disease following ethyl-EPA treatment. Neuroreport (2002) 13:123–126.
   PubMed Web of Science ®Google Scholar
• VADDADI KS, SOOSAI E, CHIU E, DINGJAN P: A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport (2002) 13:29–33.
   PubMed Web of Science ®Google Scholar
• ROSSER A, DUNNETT S: New drugs for Huntington's disease. Neuroreport (2002) 13:A21–22.
   PubMed Web of Science ®Google Scholar
• BONELLI RM, HEUBERGER C, REISECKER F: Minocycline for Huntington's disease: an open label study. Neurology (2003) 60:883–884.
   PubMed Web of Science ®Google Scholar
• VERBESSEM P, LEMIERE J, EIJNDE BO et al.: Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology (2003) 61:925–930.
   PubMed Web of Science ®Google Scholar